Pfizer will acquire AstraZeneca business | Chemical & Engineering News
Volume 94 Issue 34 | p. 15 | Concentrates
Issue Date: August 29, 2016

Pfizer will acquire AstraZeneca business

Department: Business
Keywords: antibiotics, pharmaceuticals, acquisition

Pfizer has agreed to acquire AstraZeneca’s late-stage small-molecule antibiotics business, primarily outside the U.S., for $725 million and up to $850 million in future payments. The business includes Zavicefta, recently approved in the European Union; the marketed products Merrem and Zinforo; and two products in clinical development. AstraZeneca spun off its antibiotics R&D efforts as Entasis Therapeutics last year.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment